RT Journal Article
SR Electronic
T1 High pretreatment plasma VEGF level is associated with shorter survival in paclitaxel-carboplatin treated non-small cell lung carcinoma patients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P4488
VO 42
IS Suppl 57
A1 Zsoka Weiszhar
A1 Ildiko Horvath
A1 Gyorgy Losonczy
A1 Gabriella Galffy
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P4488.abstract
AB Introduction: It is known that increased plasma VEGF levels are associated with worse outcome in lung adenocarcinoma, and survival can be prolonged by treatment with anti-VEGF antibody bevacizumab. In planocellular non-small cell lung carcinoma, relationship between VEGF level and disease outcome is considered to be more controversial.Rationale: We aimed to examine if there is relationship between pretreatment plasma VEGF level and disease outcome in non-small cell lung carcinoma patients receiving paclitaxel-carboplatin therapy.Methods: VEGF concentrations were determined by ELISA from plasma samples of chemotherapy-naive, stage IIIb or IV non-small cell lung carcinoma patients, who were selected for paclitaxel-carboplatin therapy. Response, progression, survival and other clinical parameters of the patients have been followed up for up to 18 months. Correlation and Kaplan-Mayer analyses were performed on the basis of ELISA results and clinical data of patients.Results: We found significantly higher plasma VEGF levels in patients showing progression compared to patients with no progression or partial regression. ROC analysis was performed to determine the threshhold for high pretreatment VEGF level. Log rank test showed reduced survival for patients with high baseline VEGF levels compared to the survival of patients with low VEGF levels.Conclusions: Pretreatment plasma VEGF level may be a prognostic marker for disease outcome in those advanced non-small cell lung carcinoma cases as well in which bevacizumab is not indicated.